,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['breast', 'destinybreast04']
huge standing ovation for #destinybreast04- important trial looking at refractory disease, median of 3 lines of treatment, with os benefit #asco22
@stanfordcancer Clinical Assis Prof.+ Assoc dir. of cancer quality, via @BIDMC_IM, Thoracic Onc + merging QI with health equity, brunch lover, tweets my own